William K. Oh, MD, presented “Identifying Mutations and Optimizing Use of PARP Inhibitors” during the 26th Annual Southwest Prostate Cancer Symposium conference on April 15, 2023, in Scottsdale, Arizona.
How to cite: Oh, William K. “Identifying Mutations and Optimizing Use of PARP Inhibitors.” April 15, 2023. Accessed Jan 2026. https://grandroundsinurology.com/identifying-mutations-and-optimizing-use-of-parp-inhibitors/
Identifying Mutations and Optimizing Use of PARP Inhibitors – Summary#
William K. Oh, MD, highlights the growing significance of precision medicine and the role of genetic profiling in tailoring therapeutic strategies. Dr. Oh begins by outlining the importance of identifying DNA repair gene mutations, particularly BRCA1 and BRCA2, in prostate cancer patients. These mutations, which impair the cell’s ability to repair DNA damage, render the cancer more susceptible to treatments targeting DNA repair mechanisms, such as PARP inhibitors.
Dr. Oh delves into the mechanisms of PARP inhibitors, which function by inhibiting the poly (ADP-ribose) polymerase (PARP) enzyme involved in DNA repair. By blocking this pathway, PARP inhibitors induce synthetic lethality in cancer cells harboring defective DNA repair genes, leading to cell death.
Dr. Oh discusses the importance of patient selection based on genetic profiling and the potential for combining PARP inhibitors with other therapies, such as androgen receptor signaling inhibitors and immune checkpoint inhibitors, to enhance their efficacy. He reviews ongoing clinical trials exploring these combination strategies and their preliminary results.
About the 26th Annual Southwest Prostate Cancer Symposium:
This conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
